51626 Psychometric Properties of the Vitiligo Noticeability Scale (VNS) Using Data From a Phase 2 Upadacitinib Study in Adults With Nonsegmental Vitiligo
Recommended Citation
Ezzedine K, Soliman AM, Camp HS, Ladd M, Pokrzywinski R, Sen R, Schlosser BJ, Bae J, Hamzavi I. 51626 Psychometric Properties of the Vitiligo Noticeability Scale (VNS) Using Data From a Phase 2 Upadacitinib Study in Adults With Nonsegmental Vitiligo. J Am Acad Dermatol 2024; 91(3):AB75.
Document Type
Conference Proceeding
Publication Date
9-1-2024
Publication Title
J Am Acad Dermatol
Abstract
Vitiligo Noticeability Scale (VNS) is a patient-reported outcome assessing noticeability in patients with vitiligo. Using data from a phase 2, randomized, double-blind, placebo-controlled, study with upadacitinib (NCT04927975), the test-retest reliability, validity, and responsiveness of the VNS were assessed. Randomized patients received once-daily upadacitinib (6, 11, or 22 mg) or placebo for 24 weeks. Between weeks 4 and 8, patients with clinically stable disease, defined as no change in vitiligo based on Total-Patient Global Vitiligo Assessment (T-PaGVA; n=115), showed excellent agreement between VNS scores (concordance percentage: 79.1%, Gwet AC1 0.77), reflecting VNS test-retest reliability. Similarly, there was excellent agreement between VNS scores when clinically stable disease was defined as no change in vitiligo based on Face-PaGVA (F-PaGVA; n=110; concordance percentage: 80.9%, Gwet AC1 0.79). Construct validity examined at week 24 showed that VNS had a significant but weak correlation with F-PaGVA and T-PaGVA, (Spearman’s r: −0.21, −0.2 respectively, both P<0.05). VNS response distributions were significantly different between patients showing improvements vs those with no improvements on patient global impression of change (PaGIC), T-PaGVA, and F-PaGVA scores reflecting VNS responsiveness (each P<.05). When VNS response was defined as “a lot less noticeable” or “no longer noticeable” at week 24, significantly higher proportions of clinical responders achieved VNS response compared with nonresponders (F-VASI 50: 10.9% vs 0%; F-VASI 75: 16.7% vs 1.4%; and T-VASI 50: 27.3% vs 1.3%; all P<.001). These results indicate that VNS is a valid and reliable measure, can differentiate between clinically distinct groups, and responds to improvements in vitiligo.
Volume
91
Issue
3
First Page
AB75
